Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines.

Alves, Raquel; Santos, Diogo; Jorge, Joana; Gonçalves, Ana Cristina; Catarino, Steve; Girão, Henrique; Melo, Joana Barbosa; Sarmento-Ribeiro, Ana Bela

Alves, Raquel; Santos, Diogo; Jorge, Joana; Gonçalves, Ana Cristina; Catarino, Steve; Girão, Henrique; Melo, Joana Barbosa; Sarmento-Ribeiro, Ana Bela.

Afiliação

Alves R; Laboratory of Oncobiology and Hematology (LOH), University Clinics of Hematology and Oncology, Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.
Santos D; Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.
Jorge J; Center for Innovative Biomedicine and Biotechnology (CIBB), 3004-531 Coimbra, Portugal.
Gonçalves AC; Clinical Academic Center of Coimbra (CACC), 3000-370 Coimbra, Portugal.
Catarino S; Laboratory of Oncobiology and Hematology (LOH), University Clinics of Hematology and Oncology, Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.
Girão H; Laboratory of Oncobiology and Hematology (LOH), University Clinics of Hematology and Oncology, Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.
Melo JB; Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.
Sarmento-Ribeiro AB; Center for Innovative Biomedicine and Biotechnology (CIBB), 3004-531 Coimbra, Portugal.

Molecules ; 28(3)2023 Jan 26.

Article em En | MEDLINE | ID: mdl-36770876

Assuntos

Antineoplásicos; Leucemia Mielogênica Crônica BCR-ABL Positiva; Humanos; Antineoplásicos/farmacologia; Antineoplásicos/uso terapêutico; Apoptose; Linhagem Celular Tumoral; Resistencia a Medicamentos Antineoplásicos; Proteínas de Fusão bcr-abl/genética; Proteínas de Fusão bcr-abl/metabolismo; Proteínas de Choque Térmico; Mesilato de Imatinib/farmacologia; Mesilato de Imatinib/uso terapêutico; Células K562; Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico; Leucemia Mielogênica Crônica BCR-ABL Positiva/metabolismo; Proteínas de Choque Térmico HSP90/metabolismo

Palavras-chave

chronic myeloid leukemia; heat shock protein; imatinib resistance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google